Comparison 9. Desloratadine 5 to 20 mg versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Proportion of participants with complete suppression of urticaria whilst taking H1‐antihistamines	2		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
1.1 Short‐term duration of intervention (desloratadine 5 mg)	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.2 Short‐term duration of intervention (desloratadine 10 mg)	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.3 Short‐term duration of intervention (desloratadine 20 mg)	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.4 Intermediate‐term duration of intervention (desloratadine 5 mg)	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2 Serious adverse events (i.e. serious enough to require withdrawal of treatment)	3		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.1 Intermediate‐term duration of 5 mg of intervention	3	466	Risk Ratio (M‐H, Random, 95% CI)	1.46 [0.42, 5.10]